SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 177 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $65,805 | -36.9% | 4,532 | -9.1% | 0.04% | -35.5% |
Q2 2023 | $104,294 | +19.9% | 4,983 | +20.9% | 0.06% | +29.2% |
Q1 2023 | $87,014 | -40.0% | 4,120 | -27.7% | 0.05% | -36.8% |
Q4 2022 | $145,090 | -8.7% | 5,701 | -14.0% | 0.08% | +20.6% |
Q3 2022 | $159,000 | +25.2% | 6,628 | +0.7% | 0.06% | +34.0% |
Q2 2022 | $127,000 | -16.4% | 6,584 | -24.5% | 0.05% | -30.9% |
Q1 2022 | $152,000 | -24.8% | 8,723 | -5.6% | 0.07% | -10.5% |
Q4 2021 | $202,000 | -6.0% | 9,238 | -17.8% | 0.08% | -20.0% |
Q3 2021 | $215,000 | +5.9% | 11,241 | -5.0% | 0.10% | +14.5% |
Q2 2021 | $203,000 | -23.1% | 11,835 | +0.1% | 0.08% | -25.9% |
Q1 2021 | $264,000 | +1.9% | 11,828 | +1.8% | 0.11% | +4.7% |
Q4 2020 | $259,000 | -11.9% | 11,624 | -41.6% | 0.11% | -30.5% |
Q3 2020 | $294,000 | -12.2% | 19,894 | -12.0% | 0.15% | -3.1% |
Q2 2020 | $335,000 | – | 22,596 | – | 0.16% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |